Research programme: human monoclonal antibodies - AstraZeneca/Pfizer
Latest Information Update: 06 Aug 2021
At a glance
- Originator Cambridge Antibody Technology; Pfizer
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Feb 2004 This programme is still in active development
- 24 Dec 1999 Preclinical development for Cancer in United Kingdom (Parenteral)